NephU

Empowering Patients Through Health Literacy
2022-03-02 18:30 - 21:00 (America/Denver) | Maggiano’s Little Italy Denver, 500 16th St., Suite 150, Denver, Colorado, 80202, United States
This presentation brings you concepts and resources to help improve health literacy among your patients, especially those with chronic kidney disease, as they manage the complexities of their care regimen. Health literacy is crucial for dialysis and transplant patients so they can be empowered to participate in shared decision-making. Effective communication strategies lead to better patient engagement, and engaged patients can better deal with the many challenges they face in living with kidney disease.

*Drs Lambert and Hajarnis are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).

This event is Private.

Join To View
Already A Member? Login

Featured Speakers

Location:

Nephronophthisis (NPHP) & Related Rare Cystic Kidney Diseases
2022-02-24 21:00 - 22:00 (America/New_York) | CA
About This Event

IgA Nephropathy – From Pathogenesis to Current Management
In alignment with Rare Disease Day, the NephU community wanted to explore cystic kidney diseases as they encompass a broad group of rare disorders with various characteristics. These cystic disorders can present throughout an individual’s lifetime from infancy to childhood or even adulthood. In some cases, cystic kidneys can be detected in utero.1 Tune-in to the NephU webinar where we are joined by experts, Carl Bates, MD and Rannar Airik, PhD who will describe nephronophthisis (NPHP), the most frequent genetic cause for end-stage kidney disease in the first three decades of life,2 and its associated rare genetic syndromes such as Senior-Løken Syndrome (SLNS), Joubert Syndrome (JSRD), Meckel Syndrome (MKS), and Bardet-Biedl Syndrome (BBS). Learn more about the exciting advancements in the field, as researchers have identified numerous disease-causing genes which has allowed for a better understanding of the rare cystic kidney disease pathogenesis and a higher diagnostic accuracy within the clinical setting.

References:
1. Cramer MT and Guay-Woodford LM. (2015). Adv Chronic Kidney Dis. 22(4):297-305.
2. Hildebrandt F and Zhou W. (2007). J Am Societ Nephrol. (18) 1855-1871.

*Drs Bates and Airik are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Green is an employee of OPDC.

Featuring

Moderator

Registration

Related Resources

Nephronophthisis (NPHP) & Related Rare Cystic Kidney Diseases
2022-02-24 12:00 - 13:00 (America/New_York) | CA
About This Event

IgA Nephropathy – From Pathogenesis to Current Management
In alignment with Rare Disease Day, the NephU community wanted to explore cystic kidney diseases as they encompass a broad group of rare disorders with various characteristics. These cystic disorders can present throughout an individual’s lifetime from infancy to childhood or even adulthood. In some cases, cystic kidneys can be detected in utero.1 Tune-in to the NephU webinar where we are joined by experts, Carl Bates, MD and Rannar Airik, PhD who will describe nephronophthisis (NPHP), the most frequent genetic cause for end-stage kidney disease in the first three decades of life,2 and its associated rare genetic syndromes such as Senior-Løken Syndrome (SLNS), Joubert Syndrome (JSRD), Meckel Syndrome (MKS), and Bardet-Biedl Syndrome (BBS). Learn more about the exciting advancements in the field, as researchers have identified numerous disease-causing genes which has allowed for a better understanding of the rare cystic kidney disease pathogenesis and a higher diagnostic accuracy within the clinical setting.

References:
1. Cramer MT and Guay-Woodford LM. (2015). Adv Chronic Kidney Dis. 22(4):297-305.
2. Hildebrandt F and Zhou W. (2007). J Am Societ Nephrol. (18) 1855-1871.

*Drs Bates and Airik are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Green is an employee of OPDC.

Featuring

Moderator

If you would like to register for the 9:00 pm to 10:00 pm EST broadcast, please click below:

Register For The 9:00 pm Broadcast

Registration

Related Resources

The Impact Of Systemic Racism On Black Americans' Wellness
2022-02-23 12:00 - 13:00 (America/New_York) | CA
About This Event

IgA Nephropathy – From Pathogenesis to Current Management
Over the past 2 years, during the age of COVID-19 pandemic, the spotlight has been on inequity and disadvantages faced by many Black Americans who try to access healthcare services in the United States. In celebrating Black History Month, PsychU and NephU has invited, Dr. Napoleon Higgins to discuss the ongoing challenges that Black Americans face in the pursuit of equitable healthcare access and treatment.

*Dr Higgins is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Drs Pabis and Gonzalez are employees of OPDC.

Featuring

Registration

Related Resources

Major Depressive Disorder In Chronic Kidney Disease
2022-02-15 11:45 - 13:00 (America/New_York) | Sheraton Sand Key Resort – Clearwater Beach, 1160 Gulf Blvd, Clearwater Beach, 33767, United States
Sponsored By PsychU & NephU

Limited Space Available

There is a high prevalence of depression among patients with chronic kidney disease (CKD). This presentation will examine the clinical overlap between CKD and major depressive disorder (MDD) in symptomatology, behavioral and biological mechanisms, the impact of comorbid depression on CKD outcomes, and strategies for effective management of depression in CKD.

*Drs Fornal & Emmel are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).

This event is Private.

Join To View
Already A Member? Login

Featured Speakers

Location:

The International Patient & Provider Voice In Immunoglobulin A Nephropathy (IgAN)
2022-02-10 18:00 - 19:00 (America/New_York) | CA
About This Event

IgA Nephropathy – From Pathogenesis to Current Management
IgAN is the most common primary glomerulonephritis in the world1 with an incidence of approximately 2.5/100,000/year.2 Clinical manifestations of IgAN range from asymptomatic microscopic hematuria to rapidly progressive glomerular nephritis.3 An estimated 20-40% of people with IgAN will progress to end stage kidney disease.4 Join us for an international panel discussion featuring members from the IgAN Foundation, expert nephrologists, patients & caregivers. Panelists will discuss living with IgAN; highlighting the similarities and differences in each patient’s journey, identify how providers can support patients, facilitate the patients’ understanding of IgAN management, and identify the current gaps in management.

References:

1. Knoppova B, et al. Front Immunol 2016;7:117.

2. Viola P, et al. Transl Med Commun. 2016;1:7.

3. Rodrigues JC, et al. Clin J Am Soc Nephrol. 2017;12(4):677.

4. www.igan.org. Accessed January 31, 2021.

*Drs Barratt, Rizk, Liew, Jha, and Ms Schneider, Delgado, and White are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Griboldi is an employee of OPDC.

Featuring

Introduction

Moderator

Registration

Related Resources

The International Patient & Provider Voice In Immunoglobulin A Nephropathy (IgAN)
2022-02-10 12:00 - 13:00 (America/New_York) | CA
About This Event

IgA Nephropathy – From Pathogenesis to Current Management
IgAN is the most common primary glomerulonephritis in the world1 with an incidence of approximately 2.5/100,000/year.2 Clinical manifestations of IgAN range from asymptomatic microscopic hematuria to rapidly progressive glomerular nephritis.3 An estimated 20-40% of people with IgAN will progress to end stage kidney disease.4 Join us for an international panel discussion featuring members from the IgAN Foundation, expert nephrologists, patients & caregivers. Panelists will discuss living with IgAN; highlighting the similarities and differences in each patient’s journey, identify how providers can support patients, facilitate the patients’ understanding of IgAN management, and identify the current gaps in management.

References:

1. Knoppova B, et al. Front Immunol 2016;7:117.

2. Viola P, et al. Transl Med Commun. 2016;1:7.

3. Rodrigues JC, et al. Clin J Am Soc Nephrol. 2017;12(4):677.

4. www.igan.org. Accessed January 31, 2021.

*Drs Barratt, Rizk, Liew, Jha, and Ms Schneider, Delgado, and White are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Griboldi is an employee of OPDC.

Featuring

Introduction

Moderator

If you would like to register for the 6:00 pm to 7:00 pm EST broadcast, please click below:

Register For The 6:00 pm Broadcast

Registration

Related Resources

Growing A Peritoneal Dialysis Program: A Multi-Faceted Approach
2022-01-19 18:00 - 19:00 (America/New_York) | CA
About This Event

IgA Nephropathy – From Pathogenesis to Current Management
Home dialysis modalities are increasingly emphasized in healthcare payment models and represent an important patient-centric option for renal replacement therapy. Join us for this informational discussion with Dr Ankur Shah and Dr Natasha Dave on important strategies that can be employed to establish and grow a successful peritoneal dialysis program.

*Drs Dave and Shah are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Emmel is an employee of OPDC.

Featuring

Aaron Emmel, PharmD, MHA, BCPS
Nephrology Clinical & Scientific Director

Registration

Related Resources

Growing A Peritoneal Dialysis Program: A Multi-Faceted Approach
2022-01-19 12:00 - 13:00 (America/New_York) | CA
About This Event

IgA Nephropathy – From Pathogenesis to Current Management
Home dialysis modalities are increasingly emphasized in healthcare payment models and represent an important patient-centric option for renal replacement therapy. Join us for this informational discussion with Dr Ankur Shah and Dr Natasha Dave on important strategies that can be employed to establish and grow a successful peritoneal dialysis program.

*Drs Dave and Shah are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Emmel is an employee of OPDC.

Featuring

Aaron Emmel, PharmD, MHA, BCPS
Nephrology Clinical & Scientific Director

If you would like to register for the 6:00 pm to 7:00 pm EST broadcast, please click below:

Register For The 6:00 pm Broadcast

Registration

Related Resources

The Role Of The Pharmacist In Neurocritical Care
2022-01-06 18:00 - 19:00 (America/New_York) | CA
About This Event

IgA Nephropathy – From Pathogenesis to Current Management
Hyponatremia is the most common electrolyte imbalance encountered in clinical practice. Defined as serum sodium levels of less than 135 mmol/L or 135 mEq/L, hyponatremia occurs in up to 30% of hospitalized patients.1,2 It is common in intensive care units and neurosurgical care units, but also in patients receiving anti-seizure medications, antidepressants and thiazide diuretics.3 Among hospitalized patients, hyponatremia significantly increases mortality risk, length of stay and cost of care. Severe hyponatremia can lead to cerebral edema, seizures, coma and death.4

Clinical pharmacists significantly contribute to the care of patients with hyponatremia by identifying patients at risk and the source of hyponatremia, monitor serum sodium concentration and advise on the selection of appropriate therapeutic agent, dosage and duration. Many drugs may contribute to hyponatremia; therefore, a careful review of prescribed medications may identify the cause of the electrolyte imbalance and contribute to prompt resolution.

References:
1. Wald, R. et al. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med. 2010; 170: 294–302.
2. Verbalis JG et al. Diagnosis, Evaluation, and Treatment of Hyponatremia: Expert Panel Recommendations Am J Med. 2013;126:S1-S42
3. Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008;52:144-53.
4. Patterson JH. The impact of hyponatremia. Pharmacotherapy 2011;31(5 Suppl):5S-8S.

*Dr Rhoney is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Lambert is an employee of OPDC.

Featuring

Registration

Related Resources

The Role Of The Pharmacist In Neurocritical Care
2022-01-06 12:00 - 13:00 (America/New_York) | CA
About This Event

IgA Nephropathy – From Pathogenesis to Current Management
Hyponatremia is the most common electrolyte imbalance encountered in clinical practice. Defined as serum sodium levels of less than 135 mmol/L or 135 mEq/L, hyponatremia occurs in up to 30% of hospitalized patients.1,2 It is common in intensive care units and neurosurgical care units, but also in patients receiving anti-seizure medications, antidepressants and thiazide diuretics.3 Among hospitalized patients, hyponatremia significantly increases mortality risk, length of stay and cost of care. Severe hyponatremia can lead to cerebral edema, seizures, coma and death.4

Clinical pharmacists significantly contribute to the care of patients with hyponatremia by identifying patients at risk and the source of hyponatremia, monitor serum sodium concentration and advise on the selection of appropriate therapeutic agent, dosage and duration. Many drugs may contribute to hyponatremia; therefore, a careful review of prescribed medications may identify the cause of the electrolyte imbalance and contribute to prompt resolution.

References:
1. Wald, R. et al. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med. 2010; 170: 294–302.
2. Verbalis JG et al. Diagnosis, Evaluation, and Treatment of Hyponatremia: Expert Panel Recommendations Am J Med. 2013;126:S1-S42
3. Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008;52:144-53.
4. Patterson JH. The impact of hyponatremia. Pharmacotherapy 2011;31(5 Suppl):5S-8S.

*Dr Rhoney is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Lambert is an employee of OPDC.

Featuring

If you would like to register for the 6:00 pm to 7:00 pm EST broadcast, please click below:

Register For The 6:00 pm Broadcast

Registration

Related Resources

Polycystic Kidney Disease Research – Past, Present & Future: Part III
2021-12-07 21:00 - 22:00 (America/New_York) | CA
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:

https://forms.office.com/Pages/ResponsePage.aspx?id=F_y5QW3tWUq3E9VEcJHinaIMgZ8mSTJDmw5h_sxYYP1URFZCWUVKR1o5MkQ5SDJXSFhOUkYwTTFMWC4u

About This Event

IgA Nephropathy – From Pathogenesis to Current Management
Over the past 50 years there has been significant advancement in Polycystic Kidney Disease (PKD) research which has allowed for the translation of these findings into not only an increased awareness of the disease but also improvements in clinical management. During “Polycystic Kidney Disease Research – Past, Present and Future: Part I”, we heard from leading experts, James Calvet, PhD and Arlene Chapman, MD, on the past scientific discoveries and clinical advancements made within the field of PKD research.

With all of these impressive accomplishments, leaders in the field know we must not become complacent but instead push the field even further forward in hopes of greater awareness, more management options, and improved patient outcomes. During Part II of our “Polycystic Kidney Disease Research – Past, Present, and Future” webinar we heard from two talented and emerging experts, Vishal Patel, MD & Katharina Hopp, PhD, where they discussed efforts being made to further elucidate the molecular pathways contributing to disease and shed light on cutting edge research that may one day lead to improved options for patients living with PKD.

We conclude this conversation in “Polycystic Kidney Disease Research – Past, Present and Future: Part III” and hear their perspectives on the cutting-edge techniques currently employed and how they see the field of PKD research evolving in the future.

*Dr Hopp is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Patel is an un-paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Hajarnis is an employee of OPDC.

Featuring

Registration

Related Resources

Polycystic Kidney Disease Research – Past, Present & Future: Part III
2021-12-07 12:00 - 13:00 (America/New_York) | CA
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:

https://forms.office.com/Pages/ResponsePage.aspx?id=F_y5QW3tWUq3E9VEcJHinaIMgZ8mSTJDmw5h_sxYYP1URFZCWUVKR1o5MkQ5SDJXSFhOUkYwTTFMWC4u

About This Event

IgA Nephropathy – From Pathogenesis to Current Management
Over the past 50 years there has been significant advancement in Polycystic Kidney Disease (PKD) research which has allowed for the translation of these findings into not only an increased awareness of the disease but also improvements in clinical management. During “Polycystic Kidney Disease Research – Past, Present and Future: Part I”, we heard from leading experts, James Calvet, PhD and Arlene Chapman, MD, on the past scientific discoveries and clinical advancements made within the field of PKD research.

With all of these impressive accomplishments, leaders in the field know we must not become complacent but instead push the field even further forward in hopes of greater awareness, more management options, and improved patient outcomes. During Part II of our “Polycystic Kidney Disease Research – Past, Present, and Future” webinar we heard from two talented and emerging experts, Vishal Patel, MD & Katharina Hopp, PhD, where they discussed efforts being made to further elucidate the molecular pathways contributing to disease and shed light on cutting edge research that may one day lead to improved options for patients living with PKD.

We conclude this conversation in “Polycystic Kidney Disease Research – Past, Present and Future: Part III” and hear their perspectives on the cutting-edge techniques currently employed and how they see the field of PKD research evolving in the future.

*Dr Hopp is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Patel is an un-paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Hajarnis is an employee of OPDC.

Featuring

If you would like to register for the 9:00 pm to 10:00 pm EST broadcast, please click below:

Register For The 9:00 pm Broadcast

Registration

Related Resources

Concepts & Controversies: Diabetic Kidney Disease, Diet Recommendations, A Discussion From The Experts
2021-11-30 18:00 - 19:00 (America/New_York) | CA
About This Event

IgA Nephropathy – From Pathogenesis to Current Management
This webinar will be a dialogue between two well-known Nephrologists who are experts in Chronic Kidney Disease (CKD) and Plant-based Nutrition. They will discuss the Concepts and Controversies of using a high-protein diet for weight loss and glycemic control in patients who have, or who are at risk of having, diabetic kidney disease (DKD). In this discussion, these experts will discuss the CKD Nutrition Clinical Practice Guidelines regarding DKD as well as the trade-off of high protein diets for weight loss and glycemic control vs. a low protein diet for delayed progression of CKD.

*Drs Kalantar and Joshi are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Frank is an employee of OPDC.

Featuring

Moderator

Laura Frank, PhD, MPH, RDN, CD
Nephrology Clinical & Scientific Liaison

Registration

Related Resources

Hot Topics in Nephrology – Ketogenic Diets for Polycystic Kidney Disease (PKD): Research Insights & Clinical Translation

Audio/Podcast April 10, 2025

In this episode, Dr. Thomas Weimbs discusses ketogenic diets for polycystic kidney disease (PKD), explaining the science behind ketosis and its potential impact.

Tofu Vegetable Stir-Fry

Recipe March 17, 2025

Recipe provided by Chef Anthony Valentine.

Cooking Demo: Dietary Considerations for Patients with IgA Nephropathy

On-Demand Webinar March 13, 2025

Registered Dietitian Lauren Levy and Kidney-Friendly Chef Anthony Valentine come together to bring their expertise in nutrition and IgAN, including discussing the basics of nutritional concepts – such as sodium…

Concepts & Controversies: Diabetic Kidney Disease, Diet Recommendations, A Discussion From The Experts
2021-11-30 12:00 - 13:00 (America/New_York) | CA
About This Event

IgA Nephropathy – From Pathogenesis to Current Management
This webinar will be a dialogue between two well-known Nephrologists who are experts in Chronic Kidney Disease (CKD) and Plant-based Nutrition. They will discuss the Concepts and Controversies of using a high-protein diet for weight loss and glycemic control in patients who have, or who are at risk of having, diabetic kidney disease (DKD). In this discussion, these experts will discuss the CKD Nutrition Clinical Practice Guidelines regarding DKD as well as the trade-off of high protein diets for weight loss and glycemic control vs. a low protein diet for delayed progression of CKD.

*Drs Kalantar and Joshi are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Frank is an employee of OPDC.

Featuring

Moderator

Laura Frank, PhD, MPH, RDN, CD
Nephrology Clinical & Scientific Liaison

If you would like to register for the 6:00 pm to 7:00 pm EST broadcast, please click below:

Register For The 6:00 pm Broadcast

Registration

Related Resources

Hot Topics in Nephrology – Ketogenic Diets for Polycystic Kidney Disease (PKD): Research Insights & Clinical Translation

Audio/Podcast April 10, 2025

In this episode, Dr. Thomas Weimbs discusses ketogenic diets for polycystic kidney disease (PKD), explaining the science behind ketosis and its potential impact.

Tofu Vegetable Stir-Fry

Recipe March 17, 2025

Recipe provided by Chef Anthony Valentine.

Cooking Demo: Dietary Considerations for Patients with IgA Nephropathy

On-Demand Webinar March 13, 2025

Registered Dietitian Lauren Levy and Kidney-Friendly Chef Anthony Valentine come together to bring their expertise in nutrition and IgAN, including discussing the basics of nutritional concepts – such as sodium…

The Evolution Of Managing Patients With Anemia Due To Chronic Kidney Disease
2021-11-16 18:00 - 19:00 (America/New_York) | CA
About This Event

IgA Nephropathy – From Pathogenesis to Current Management
Anemia is a well-known complication of chronic kidney disease (CKD) and the overall impact it has on patients who suffer from CKD is significant. In this informative webinar, renowned anemia expert, Dr Jay B Wish, will walk us through how managing patients with anemia in CKD has evolved over time and highlight recent scientific advancements that could potentially change the treatment landscape of anemia in CKD. *Dr Wish is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Mr George is an employee of ODPC.

Featuring

Sean George, PA-C, MHS
Nephrology Medical Science Director

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Sean George PA-C, MHS is a Physician Assistant who currently works as a Nephrology Medical Science Director for Otsuka Pharmaceutical Commercialization and Development. He has been with Otsuka in his current role for 2 years supporting the Nephrology division. Prior to joining industry, he practiced in a private practice Nephrology clinic for 4 years managing patients with chronic kidney disease including their associated co-morbidities, anemia secondary to CKD, acute kidney injury, and end stage renal disease. In addition to his clinical work, he served on the Executive Committee for Advanced Practitioners with the National Kidney Foundation for 3 consecutive years as member-at-large, secretary, and research chair. Sean earned his Physician Assistant/Masters Health Science from the University of Oklahoma College of Medicine. He is currently licensed in the state of Oklahoma and certified with the National Commission on Certification of Physician Assistants.

Registration

Related Resources

The Evolution Of Managing Patients With Anemia Due To Chronic Kidney Disease
2021-11-16 12:00 - 13:00 (America/New_York) | CA
About This Event

IgA Nephropathy – From Pathogenesis to Current Management
Anemia is a well-known complication of chronic kidney disease (CKD) and the overall impact it has on patients who suffer from CKD is significant. In this informative webinar, renowned anemia expert, Dr Jay B Wish, will walk us through how managing patients with anemia in CKD has evolved over time and highlight recent scientific advancements that could potentially change the treatment landscape of anemia in CKD.

*Dr Wish is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Mr George is an employee of ODPC.

Featuring

Sean George, PA-C, MHS
Nephrology Medical Science Director

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Sean George PA-C, MHS is a Physician Assistant who currently works as a Nephrology Medical Science Director for Otsuka Pharmaceutical Commercialization and Development. He has been with Otsuka in his current role for 2 years supporting the Nephrology division. Prior to joining industry, he practiced in a private practice Nephrology clinic for 4 years managing patients with chronic kidney disease including their associated co-morbidities, anemia secondary to CKD, acute kidney injury, and end stage renal disease. In addition to his clinical work, he served on the Executive Committee for Advanced Practitioners with the National Kidney Foundation for 3 consecutive years as member-at-large, secretary, and research chair. Sean earned his Physician Assistant/Masters Health Science from the University of Oklahoma College of Medicine. He is currently licensed in the state of Oklahoma and certified with the National Commission on Certification of Physician Assistants.

If you would like to register for the 6:00 pm to 7:00 pm EST broadcast, please click below:

Register For The 6:00 pm Broadcast

Registration

Related Resources

Diet Management In Autosomal Dominant Polycystic Kidney Disease (ADPKD): Ketogenic Diet - Part 3
2021-11-10 21:00 - 22:00 (America/New_York) | CA
Part 1 of this series described the fact that ADPKD is a metabolic reprogramming disease, which may benefit from novel diet strategies such as a ketogenic diet. Part 2 of this 3- part series discussed the use of a Plant-Focused Ketogenic Diet (PFKD) program for improved ADPKD outcomes. In Part 3 of this series, we will focus on meal planning, meal preparation and a food demonstration describing a “day in the life” when following a Plant-Focused Ketogenic Diet.

*Ms Bruen and Mr Sunwold are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Frank is an employee of OPDC.

This event is Private.

Join To View
Already A Member? Login

Featured Speakers

Moderator

Laura Frank, PhD, MPH, RDN, CD
Nephrology Clinical & Scientific Liaison

Location

Online

Diet Management In Autosomal Dominant Polycystic Kidney Disease (ADPKD): Ketogenic Diet - Part 3
2021-11-10 12:00 - 13:00 (America/New_York) | CA
Part 1 of this series described the fact that ADPKD is a metabolic reprogramming disease, which may benefit from novel diet strategies such as a ketogenic diet. Part 2 of this 3- part series discussed the use of a Plant-Focused Ketogenic Diet (PFKD) program for improved ADPKD outcomes. In Part 3 of this series, we will focus on meal planning, meal preparation and a food demonstration describing a “day in the life” when following a Plant-Focused Ketogenic Diet.

*Ms Bruen and Mr Sunwold are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Frank is an employee of OPDC.

This event is Private.

Join To View
Already A Member? Login

If you would like to register for the 9:00 pm to 10:00 pm EST broadcast, please click below:

Register For The 9:00 pm Broadcast

Featured Speakers

Moderator

Laura Frank, PhD, MPH, RDN, CD
Nephrology Clinical & Scientific Liaison

Location

Online

The Role Of The Pharmacist In Chronic Kidney Disease
2021-10-28 21:00 - 22:00 (America/New_York) | CA
Clinical pharmacy services have the potential to contribute significantly to the multidisciplinary team by providing safe, effective, and economic care for patients. Given recent practice developments (e.g. polypharmacy reviews and pharmacist prescribing), there is a need to provide a current synthesis of evidence-based characteristics and outcomes of clinical pharmacy practice in treating patients with chronic kidney disease (CKD). Dr. Calvin Meaney and Dr. Katie Cardone outline the role of both inpatient and outpatient clinical pharmacy services as well as discuss medication therapy challenges in managing patients with CKD.

*Dr Meaney and Ms Cardone are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Voigt is an employee of OPDC.

This event is Private.

Join To View
Already A Member? Login

Featured Speakers

Lisa Voigt, PharmD, BCPS, BCCCP
Nephrology Senior Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Lisa Voigt, PharmD, BCPS, BCCCP is a PharmD who works as a Senior Medical Science Liaison in Nephrology with Otsuka Pharmaceutical Development & Commercialization, Inc. Prior to joining Otsuka in 2019, Dr Voigt practiced as a Medical Intensive Care Unit and Surgical Intensive Care Unit Pharmacist for 15 years at a tertiary medical center in Buffalo, NY. She earned her Bachelor of Science degree in Pharmaceutics and PharmD from the SUNY Buffalo School of Pharmacy and Pharmaceutical Sciences. She completed a Post-Graduate year 1 Pharmacy Residency and Post-Graduate year 2 Critical Care/Emergency Medicine Pharmacy Residency at the University of Rochester Medical Center in Rochester, NY. Dr Voigt is a Past-President of the New York State Council of Health-system Pharmacists and has served on the Board of Directors for the past 10 years. She is also Past-President of the Western New York Society of Health-system Pharmacists. She is an Adjunct Assistant Professor at SUNY Buffalo, School of Pharmacy and Pharmaceutical Sciences. Dr Voigt holds board certifications in pharmacotherapy as well as critical care pharmacotherapy.

Location

Online

The Role Of The Pharmacist In Chronic Kidney Disease
2021-10-28 12:00 - 13:00 (America/New_York) | CA
Clinical pharmacy services have the potential to contribute significantly to the multidisciplinary team by providing safe, effective, and economic care for patients. Given recent practice developments (e.g. polypharmacy reviews and pharmacist prescribing), there is a need to provide a current synthesis of evidence-based characteristics and outcomes of clinical pharmacy practice in treating patients with chronic kidney disease (CKD). Dr. Calvin Meaney and Dr. Katie Cardone outline the role of both inpatient and outpatient clinical pharmacy services as well as discuss medication therapy challenges in managing patients with CKD.

*Dr Meaney and Ms Cardone are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Voigt is an employee of OPDC.

This event is Private.

Join To View
Already A Member? Login

If you would like to register for the 9:00 pm to 10:00 pm EDT broadcast, please click below:

Register For The 9:00 pm Broadcast

Featured Speakers

Lisa Voigt, PharmD, BCPS, BCCCP
Nephrology Senior Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Lisa Voigt, PharmD, BCPS, BCCCP is a PharmD who works as a Senior Medical Science Liaison in Nephrology with Otsuka Pharmaceutical Development & Commercialization, Inc. Prior to joining Otsuka in 2019, Dr Voigt practiced as a Medical Intensive Care Unit and Surgical Intensive Care Unit Pharmacist for 15 years at a tertiary medical center in Buffalo, NY. She earned her Bachelor of Science degree in Pharmaceutics and PharmD from the SUNY Buffalo School of Pharmacy and Pharmaceutical Sciences. She completed a Post-Graduate year 1 Pharmacy Residency and Post-Graduate year 2 Critical Care/Emergency Medicine Pharmacy Residency at the University of Rochester Medical Center in Rochester, NY. Dr Voigt is a Past-President of the New York State Council of Health-system Pharmacists and has served on the Board of Directors for the past 10 years. She is also Past-President of the Western New York Society of Health-system Pharmacists. She is an Adjunct Assistant Professor at SUNY Buffalo, School of Pharmacy and Pharmaceutical Sciences. Dr Voigt holds board certifications in pharmacotherapy as well as critical care pharmacotherapy.

Location

Online

Polycystic Kidney Disease Research - Past, Present & Future: Part II
2021-10-21 21:00 - 22:00 (America/New_York) | CA
Over the past 50 years there has been significant advancement in Polycystic Kidney Disease (PKD) research which has allowed for the translation of these findings into not only an increased awareness of the disease but also improvements in clinical management. During “Polycystic Kidney Disease Research – Past, Present and Future: Part I”, we heard from leading experts, James Calvet, PhD and Arlene Chapman, MD, on the past scientific discoveries and clinical advancements made within the field of PKD research.

With all of these impressive accomplishments, leaders in the field know we must not become complacent but instead push the field even further forward in hopes of greater awareness, more management options, and improved patient outcomes. Join us for Part II of our “Polycystic Kidney Disease Research – Past, Present, and Future” webinar where talented and emerging experts, Vishal Patel, MD & Katharina Hopp, PhD discuss efforts being made to further elucidate the molecular pathways contributing to disease and shed light on cutting edge research that may one day lead to improved options for patients living with PKD.

*Dr Hopp is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Patel is an unpaid consultant of ODPC. Dr Hajarnis is an employee of OPDC.

This event is Private.

Join To View
Already A Member? Login

Featured Speakers

Sachin Hajarnis, PhD
Nephrology Medical Science Director

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Sachin Hajarnis, PhD is a Senior Medical Science Liaison at Otsuka Pharmaceuticals. Dr Hajarnis has a Bachelors and Masters in Life Sciences from University of Mumbai, India. He obtained a PhD in Biochemistry and Molecular Biology from Colorado State University. Dr Hajarnis joined the University of Texas Southwestern Medical school in Dallas, as a post-doctoral fellow in the department of Nephrology where he performed basic research on various aspects of Polycystic Kidney Disease (PKD). He continued his studies on the role of micro-RNAs in PKD as a Research Scientist for several years before joining his current position at Otsuka.

Location

Online

Polycystic Kidney Disease Research - Past, Present & Future: Part II
2021-10-21 12:00 - 13:00 (America/New_York) | CA
Over the past 50 years there has been significant advancement in Polycystic Kidney Disease (PKD) research which has allowed for the translation of these findings into not only an increased awareness of the disease but also improvements in clinical management. During “Polycystic Kidney Disease Research – Past, Present and Future: Part I”, we heard from leading experts, James Calvet, PhD and Arlene Chapman, MD, on the past scientific discoveries and clinical advancements made within the field of PKD research.

With all of these impressive accomplishments, leaders in the field know we must not become complacent but instead push the field even further forward in hopes of greater awareness, more management options, and improved patient outcomes. Join us for Part II of our “Polycystic Kidney Disease Research – Past, Present, and Future” webinar where talented and emerging experts, Vishal Patel, MD & Katharina Hopp, PhD discuss efforts being made to further elucidate the molecular pathways contributing to disease and shed light on cutting edge research that may one day lead to improved options for patients living with PKD.

*Dr Hopp is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Patel is an unpaid consultant of ODPC. Dr Hajarnis is an employee of OPDC.

This event is Private.

Join To View
Already A Member? Login

If you would like to register for the 9:00 pm to 10:00 pm EDT broadcast, please click below:

Register For The 9:00 pm Broadcast

Featured Speakers

Sachin Hajarnis, PhD
Nephrology Medical Science Director

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Sachin Hajarnis, PhD is a Senior Medical Science Liaison at Otsuka Pharmaceuticals. Dr Hajarnis has a Bachelors and Masters in Life Sciences from University of Mumbai, India. He obtained a PhD in Biochemistry and Molecular Biology from Colorado State University. Dr Hajarnis joined the University of Texas Southwestern Medical school in Dallas, as a post-doctoral fellow in the department of Nephrology where he performed basic research on various aspects of Polycystic Kidney Disease (PKD). He continued his studies on the role of micro-RNAs in PKD as a Research Scientist for several years before joining his current position at Otsuka.

Location

Diet Management In Autosomal Dominant Polycystic Kidney Disease (ADPKD): Ketogenic Diet - Part 2
2021-10-13 21:00 - 22:00 (America/New_York) | CA
Part 1 of this series described the fact that ADPKD is a metabolic reprogramming disease, which may benefit from novel diet strategies such as a ketogenic diet. Part 2 of this 3-part series will discuss and describe the use of a Plant-Focused Ketogenic Diet (PFKD) program for improved ADPKD outcomes. We will set the stage for Part 3 of this series, where we will focus on meal planning, meal preparation and a food demonstration describing a “day in the life” when following a Plant-Focused Ketogenic Diet.

*Ms Bruen is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Frank is an employee of OPDC.

This event is Private.

Join To View
Already A Member? Login

Featured Speakers

Laura Frank, PhD, MPH, RDN, CD
Nephrology Clinical & Scientific Liaison

Location

Online

Diet Management In Autosomal Dominant Polycystic Kidney Disease (ADPKD): Ketogenic Diet - Part 2
2021-10-13 12:00 - 13:00 (America/New_York) | CA
Part 1 of this series described the fact that ADPKD is a metabolic reprogramming disease, which may benefit from novel diet strategies such as a ketogenic diet. Part 2 of this 3-part series will discuss and describe the use of a Plant-Focused Ketogenic Diet (PFKD) program for improved ADPKD outcomes. We will set the stage for Part 3 of this series, where we will focus on meal planning, meal preparation and a food demonstration describing a “day in the life” when following a Plant-Focused Ketogenic Diet.

*Ms Bruen is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Frank is an employee of OPDC.

This event is Private.

Join To View
Already A Member? Login

If you would like to register for the 9:00 pm to 10:00 pm EDT broadcast, please click below:

Register For The 9:00 pm Broadcast

Featured Speakers

Laura Frank, PhD, MPH, RDN, CD
Nephrology Clinical & Scientific Liaison

Location

Online

The Utility Of Clinical Genomics In Kidney Disease: International Perspectives - Part 2
2021-10-06 18:00 - 19:00 (America/New_York) | CA
(October 7, 8:00 am – 9:00 am AEST)

Advances in genomic technologies in recent years have led to an increasing role for clinical genomics in nephrology practice. While this advance brings the promise of positive outcomes such as clearer diagnoses and robust information to guide clinical management, it also opens a range of logistical, technical, and ethical points for the nephrologist to consider.

Join us for part 2 of this informative international webinar where Professor Andrew Mallett, nephrologist and clinical researcher (Australia), and Dr Hila Rasouly, research scientist and genetic counselor (USA), discuss clinical genomics and its applications in kidney disease, including genetic testing for diagnosis and prognosis and the question of determining which patients to test, barriers to access, global differences across healthcare landscapes, and implications for the patient.

Part 1 of this webinar can be watched here:

Archived Webinar – The Utility Of Clinical Genomics In Kidney Disease: International Perspectives – Part 1 – NephU

*Professor Andrew Mallett and Dr Hila Milo Rasouly are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Sundar is an employee of OPDC.

This event is Private.

Join To View
Already A Member? Login

Featured Speakers

Moderator

Shirin Sundar, PhD
Nephrology Senior Clinical & Scientific Liaison

Location

Online

The Utility Of Clinical Genomics In Kidney Disease: International Perspectives - Part 2
2021-10-06 12:00 - 13:00 (America/New_York) | CA
Advances in genomic technologies in recent years have led to an increasing role for clinical genomics in nephrology practice. While this advance brings the promise of positive outcomes such as clearer diagnoses and robust information to guide clinical management, it also opens a range of logistical, technical, and ethical points for the nephrologist to consider.

Join us for part 2 of this informative international webinar where Professor Andrew Mallett, nephrologist and clinical researcher (Australia), and Dr Hila Rasouly, research scientist and genetic counselor (USA), discuss clinical genomics and its applications in kidney disease, including genetic testing for diagnosis and prognosis and the question of determining which patients to test, barriers to access, global differences across healthcare landscapes, and implications for the patient.

Part 1 of this webinar can be watched here:

Archived Webinar – The Utility Of Clinical Genomics In Kidney Disease: International Perspectives – Part 1 – NephU

*Professor Andrew Mallett and Dr Hila Milo Rasouly are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Sundar is an employee of OPDC.

This event is Private.

Join To View
Already A Member? Login

If you would like to register for the 6:00 pm to 7:00 pm EDT broadcast (October 7, 8:00 am – 9:00 am AEST), please click below:

Register For The 6:00 pm Broadcast (October 7, 8:00 am – 9:00 am AEST)

Featured Speakers

Moderator

Shirin Sundar, PhD
Nephrology Senior Clinical & Scientific Liaison

Location

Online

Racial Disparities In Autosomal Dominant Polycystic Kidney Disease
2021-09-28 21:00 - 22:00, 2021-09-28 18:00 - 19:00 (America/New_York) | CA
Did you know that Black patients with autosomal dominant polycystic kidney disease (ADPKD) progress to kidney failure earlier than White patients?1,2 Watch a rebroadcast of this virtual panel discussion, led by nephrology experts, where you can hear about the racial disparities that exist in autosomal dominant polycystic kidney disease (ADPKD), underrepresentation of Black Americans and other people of color in clinical trials, and implicit bias that may impact the treatment of those with ADPKD.

References

Yium J et al. J Am Soc Nephrol. 1994;4(9):1670–4.Murphy et al. BMC Nephrology (2019) 20:55.

*Drs Neera Dahl, and Loretta Jackson Brown are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Drs Charlotte Jones-Burton & Shirin Sundar are employees of OPDC.

The findings and conclusions in this presentation are those of the author and do not necessarily represent the views of the Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry.

This event is Private.

Join To View
Already A Member? Login

Featured Speakers

Shirin Sundar, PhD
Nephrology Senior Clinical & Scientific Liaison

Location

Online

Racial Disparities In Autosomal Dominant Polycystic Kidney Disease
2021-09-28 12:00 - 13:00 (America/New_York) | CA
Did you know that Black patients with autosomal dominant polycystic kidney disease (ADPKD) progress to kidney failure earlier than White patients?1,2 Watch a rebroadcast of this virtual panel discussion, led by nephrology experts, where you can hear about the racial disparities that exist in autosomal dominant polycystic kidney disease (ADPKD), underrepresentation of Black Americans and other people of color in clinical trials, and implicit bias that may impact the treatment of those with ADPKD.

References

Yium J et al. J Am Soc Nephrol. 1994;4(9):1670–4.Murphy et al. BMC Nephrology (2019) 20:55.

*Drs Neera Dahl, and Loretta Jackson Brown are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Drs Charlotte Jones-Burton & Shirin Sundar are employees of OPDC.

The findings and conclusions in this presentation are those of the author and do not necessarily represent the views of the Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry.

This event is Private.

Join To View
Already A Member? Login

If you would like to register for the 6:00 pm to 7:00 pm EDT broadcast or 9:00 pm to 10:00 pm EDT broadcast, please click below:

Register For The 6:00 pm Broadcast

Register For The 9:00 pm Broadcast

Featured Speakers

Shirin Sundar, PhD
Nephrology Senior Clinical & Scientific Liaison

Location

Online
